Figure 2
Figure 2. Jak2V617F MPN-initiating cells dominate hematopoiesis over time. (A) The percentage of Jak2+/VF (VF) donor myeloid chimerism assessed in peripheral blood (PB) from lethally irradiated secondary recipients of Jak2+/VFE2Acre+ and Jak2+/+E2Acre+ LSK cells in 75:25, 50:50, and 25:75 ratios, respectively, measured 5-65 weeks posttransplantation (mean ± SEM; n = 2-6 in each group). (B) Jak2+/VF (VF) to Jak2+/+ (WT) chimerism ratios assessed in BM SLAM LSK, LSK, and LK compartments from lethally irradiated WT recipients of Jak2+/VFE2Acre+ and Jak2+/+E2Acre+ LSK cells in a 25:75 ratio, measured 65 weeks after transplantation (mean ± SEM; n = 2 in each group). (C) Histopathologic (HE) sections of BM and spleen (SPL) from representative mice transplanted with Jak2+/VFE2Acre+ and Jak2+/+E2Acre+ LSK cells in 50:50 or 25:75 ratios, demonstrating erythroid and megakaryocytic hyperplasia in both groups.

Jak2V617F MPN-initiating cells dominate hematopoiesis over time. (A) The percentage of Jak2+/VF (VF) donor myeloid chimerism assessed in peripheral blood (PB) from lethally irradiated secondary recipients of Jak2+/VFE2Acre+ and Jak2+/+E2Acre+ LSK cells in 75:25, 50:50, and 25:75 ratios, respectively, measured 5-65 weeks posttransplantation (mean ± SEM; n = 2-6 in each group). (B) Jak2+/VF (VF) to Jak2+/+ (WT) chimerism ratios assessed in BM SLAM LSK, LSK, and LK compartments from lethally irradiated WT recipients of Jak2+/VFE2Acre+ and Jak2+/+E2Acre+ LSK cells in a 25:75 ratio, measured 65 weeks after transplantation (mean ± SEM; n = 2 in each group). (C) Histopathologic (HE) sections of BM and spleen (SPL) from representative mice transplanted with Jak2+/VFE2Acre+ and Jak2+/+E2Acre+ LSK cells in 50:50 or 25:75 ratios, demonstrating erythroid and megakaryocytic hyperplasia in both groups.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal